Emergent BioSolutions Gets FDA Approval For Inhalational Anthrax Drug Anthrasil

(RTTNews) - Specialty biopharma company Emergent BioSolutions Inc. (EBS) Wednesday said it received U.S. Food and Drug Administration approval for its Anthrasil or AIGIV, for treatment of inhalational anthrax in combination with appropriate antibacterial drugs. The company said Anthrasil is now qualified for seven years of market exclusivity and it is the only FDA-approved polyclonal therapeutic for the treatment of anthrax disease.

Emergent BioSolutions will receive a milestone payment of $7 million as per the contract with the Biomedical Advanced Research and Development Authority or BARDA.

Adam Havey, executive vice president and president biodefense division at Emergent BioSolutions, said, "Anthrasil remains an integral part of the U.S. government's strategic national stockpile and we are committed to working collaboratively with BARDA and CDC to further advance this program."